A--PRECLINICAL MEDICATIONS SCREENING IN DEPENDENCE MO
ID: 75N94024R00003Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NICHDBETHESDA, MD, 20817, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH (AJ11)

Original Source

https://sam.gov/opp/adfcd790fd09471abca59f646e1c28ef/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for a contract focused on preclinical medications screening in models of Alcohol Use Disorder (AUD). The objective of this procurement is to conduct blind testing of compounds supplied by developers using mouse models, with the contractor responsible for generating analyses and reports throughout the project. This initiative is crucial for advancing research in alcohol use disorder treatments and ensuring compliance with NIH policies on reproducibility and animal welfare. Proposals are due by September 18, 2024, with the contract period commencing on December 1, 2024, and extending through November 30, 2031. Interested parties can contact Lisa Schaupp at lisa.schaupp@nih.gov or 301-827-8135 for further information.

    Point(s) of Contact
    SCHAUPP, LISA L
    (301) 827-8135
    lisa.schaupp@nih.gov
    Files
    Title
    Posted
    Amend_01_Att_01_02_03_RFP_75N94024R00003_8_23_24_0001.pdf
    Amendment 01 to RFP 75N94024R00003 outlines special contract requirements regarding information and physical security for government-owned/contractor-operated (GOCO) and contractor-owned/contractor-operated (COCO) systems. Key provisions include compliance with federal security regulations, including the HHS Information Security and Privacy Policy and NIST guidelines. Contractors must obtain a valid Authority to Operate (ATO) within three months post-award, and submit a System Security Plan (SSP) and Plan of Action and Milestones (POA&M) detailing security controls and vulnerability management. Furthermore, contractors must ensure continuous monitoring of IT assets, apply secure coding practices, and facilitate government access for security assessments. The document specifies guidelines for end-of-life software, use of secured devices, data rights, and cybersecurity supply chain risk management. Additionally, contractors are mandated to comply with Section 508 of the Rehabilitation Act regarding electronic accessibility of deliverables. The contract concerns a preclinical testing program for drugs aimed at treating Alcohol Use Disorder and is set to begin on December 1, 2024, lasting 12 months with six options for extension. This RFP emphasizes the government's commitment to upholding stringent security and accessibility standards in conjunction with advancing public health research.
    att_24_links.pdf
    The document is a compilation of attachments and resources related to federal and state/local Request for Proposals (RFPs) for the National Institutes of Health (NIH). It includes various essential components required for proposal submissions, such as guidelines for proposal packaging, intent response sheets, a statement of work for an Indefinite Delivery Indefinite Quantity (IDIQ) contract, and specified reporting requirements and deliverables. Additional key items consist of technical proposal forms, cost summary links, and compliance certifications, along with instructions for invoicing and financial requests. Furthermore, it outlines specific templates for small business subcontracting plans, government property scheduling, and employee suitability investigations. The document emphasizes the necessity of safeguarding non-public information through contractor agreements. Task orders, including statements of work for pre-clinical contract administration and compound testing, are also described. The comprehensive nature of these attachments indicates a structured approach to facilitate proposals, ensuring clarity and adherence to federal guidelines, thereby supporting the government's procurement processes. This intricate framework reinforces the commitment to maintain robustness and transparency in public spending.
    Presolicitation_Notice_75N94024R00003_PreClinical_Dependency_Mice_2.pdf
    SBCX_Industry_Subcontracting_Guide_0002.pdf
    The "HHS Industry User Guide for Subcontracting Plan Reviews" serves as a comprehensive manual for vendors required to submit subcontracting plans to the Department of Health and Human Services (HHS). The document outlines the process for accessing and reviewing subcontracting plans through the SBCX platform, which includes sections for project information, subcontracting goals, documentation, and communication with HHS officials. Vendors are guided to identify the type of subcontracting plan, report eligible subcontracting expenditures, provide necessary goal data, designate a Subcontracting Program Administrator, and detail efforts to include small businesses. They must certify compliance and submit the plan for approval. The evaluation process involves multiple approvers, ensuring thorough oversight. The guide emphasizes the importance of compliance with subcontracting goals within the context of federal and local RFPs, aligning with broader government objectives to engage small businesses in federal contracting opportunities. The document ultimately facilitates a structured approach to subcontracting plan submissions and reviews, ensuring adherence to government standards.
    Sol_75N94024R00003_Amd_0001.pdf
    The document serves as an amendment to solicitation number 75N94024R00003 issued by the National Institute of Child Health (NICHD), detailing modifications to the initial request related to a contract for "Preclinical Medications Screening in Dependence Models of Alcohol Use Disorder." Key updates include the addition of a new section on information security, revisions to Section M.6 for compliance with Section 508 guidelines, and amendments to Attachment 21 to include the necessary Section 508 language. The performance period for the contract is specified from December 1, 2024, to November 30, 2031. In accordance with federal requirements, offers must acknowledge receipt of this amendment to avoid rejection. The document emphasizes adherence to rigorous standards for information security and accessibility, reflecting the government’s commitment to ensuring equitable access to information and services in the procurement process. This amendment is a formal step in the federal contracting process, aligning with guidelines for soliciting offers and modifying existing contracts.
    Sol_75N94024R00003_Amd_0002.pdf
    The document pertains to Amendment 02 of Solicitation No. 75N94024R00003 issued by the National Institute of Child Health (NICHD), part of the National Institutes of Health (NIH). The amendment outlines important procedural guidelines for potential offerors, emphasizing the necessity of acknowledging receipt of the amendment by a specified date to avoid the rejection of offers. The primary focus is on the solicitation titled "Preclinical Medications Screening in Dependence Models of Alcohol Use Disorder," with a performance period set from December 1, 2024, to November 30, 2031. Key changes in this amendment include provisions for submitting written questions to Ms. Sarah Bank by September 4, 2024, and inclusion of a guide for subcontracting plan reviews. It also updates a specific section to incorporate a link for the SBCX Subcontracting Plan Review. The document reinforces the need for compliance with the call for amendments and modifications applicable to governmental contracts, highlighting the importance of clear communication and documentation in federal contract procedures. Overall, it serves as a crucial resource for contractors interested in the mentioned solicitation, facilitating clarity and proper protocol adherence in the submission process.
    Sol_75N94024R00003.pdf
    The National Institutes of Health (NIH) issued a Request for Proposals (RFP) for a contract related to preclinical medication screening in models of Alcohol Use Disorder (AUD). The project aims to conduct blind testing of compounds supplied by developers in mice, with analyses and reports to be generated. Proposals are due by September 18, 2024, and the contract period spans from December 1, 2024, to November 30, 2031. This contract, accessible to various small businesses, outlines estimated costs, payment terms, and specific performance requirements, including adherence to NIH policies on reproducibility, animal welfare, and financial conflicts of interest. The contractor will provide all necessary personnel and resources, submitting regular progress reports and ensuring compliance with federal procurement regulations. Rigorous standards for monitoring and response to conflicts of interest are established, emphasizing the contractor’s accountability for transparent research practices. The successful offeror will engage in a structured process for task orders, ensuring alignment with NIH directives and the overall mission of advancing alcohol research.
    Sources_Sought_75N94024R00003_1.pdf
    Statement_of_Work_dated_2_14_2024_1.pdf
    Similar Opportunities
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Phase I clinical trials aimed at developing small molecule and biologics therapeutics, as outlined in RFP No. 75N95024R00086. The selected contractor will be responsible for comprehensive services including protocol development, trial management, and reporting to regulatory agencies, with a focus on safety, tolerability, and pharmacokinetics of the investigational therapeutics. This initiative is crucial for advancing therapeutic development in the field of neurology, ensuring compliance with FDA and ICH GCP standards throughout the trial process. Proposals are due by October 3, 2024, with a contract performance period from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. Interested parties can contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301 for further information.
    PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the preparation and distribution of research drug products under a presolicitation notice. The contract will involve acquiring, importing, and exporting drugs and chemical compounds, as well as developing and analyzing various drug dosage forms, including marijuana and nicotine research cigarettes, to support drug abuse and addiction research. This contract is critical for maintaining a reliable supply of authentic controlled and uncontrolled drug compounds for the research community, with an anticipated award of one indefinite delivery, indefinite quantity (IDIQ) contract over a five-year period. Interested parties must possess a current DEA registration and comply with FDA’s current Good Manufacturing Practices, with proposals due approximately 45 days after the release of the RFP, expected on or about September 20, 2024. For further inquiries, contact Scott Duernberger at scott.duernberger@nih.gov or 301-594-0670.
    Using humanized mouse models of NNMT and SULT1A1 for follow-up efficacy studies
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Center for Advancing Translational Sciences (NCATS), intends to award a sole-source contract to GemPharmatech, LLC for follow-up efficacy studies utilizing humanized mouse models of NNMT and SULT1A1. The primary objective of this procurement is to conduct a series of studies, including a Maximum Tolerated Dose (MTD) study, a pharmacokinetic (PK) study, and an efficacy study, to evaluate small molecule inhibitors developed by NCATS, necessitating the creation of mouse models that express human versions of the enzymes involved. This research is critical for advancing the development of therapeutics targeting various human diseases, and the project is expected to span 12 months. Interested parties may submit their capabilities by September 17, 2024, to Michelle Cecilia at michelle.cecilia@nih.gov, with the contract value and specific funding details not disclosed in the announcement.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances. The primary objective is to ensure the Division of Preclinical Innovation (DPI) receives drug substances of adequate quality and quantity to support preclinical and Investigational New Drug (IND)-enabling studies, adhering to current Good Manufacturing Practice (cGMP) standards. This procurement is crucial for advancing therapeutics from preclinical stages to market readiness, emphasizing a multidisciplinary approach and compliance with regulatory requirements throughout the drug development pipeline. The Request for Proposals (RFP) is expected to be released on or about October 4, 2024, with contract awards anticipated in the second quarter of FY2025. Interested parties may contact Samson Shifaraw at samson.shifaraw@nih.gov for further information.
    ThermoFisher branded Invitrogen ProcartaPlex immunoassay kits (Brand Name restriction)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for ThermoFisher branded Invitrogen ProcartaPlex immunoassay kits as part of a combined synopsis/solicitation. The procurement aims to acquire specific immunoassay kits necessary for testing human cytokine and chemokine levels in serum and saliva samples from individuals with alcohol use disorder, which is critical for ongoing research into the effects of alcohol consumption on health. The required kits must be capable of detecting and quantifying a panel of 80 targets simultaneously and are essential for ensuring continuity and comparability across various studies conducted by the NIH Clinical Center. Interested vendors must submit their offers by September 17, 2024, to Lu Chang at lu-chang.lu@nih.gov, including pricing and delivery timelines, as late submissions will not be considered.
    Surveys and Cognitive Tasks
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), is seeking a vendor for a non-competitive contract to provide account management, planning, and maintenance for online crowd-sourced surveys and cognitive tasks related to depression and anxiety. The primary objective is to facilitate participation in these surveys for individuals both with and without mental health conditions, thereby supporting research efforts in this critical area. This procurement falls under NAICS code 541910, with a contract period of one year, and is scheduled for award on or around September 23, 2024. Interested parties must submit their capability statements and proposals by September 23, 2024, at 9:00 a.m. Eastern Standard Time, to Robin Knightly at Robin.Knightly@nih.gov.
    A--BPCA Pediatric Trials Network
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for an Indefinite Quantity Contract to establish and manage the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network. This initiative aims to create a robust infrastructure for conducting pediatric clinical trials, emphasizing compliance with federal regulations and ethical standards in research practices. The contract, which has a performance period from May 19, 2025, to May 18, 2033, offers a minimum compensation of $2,500 and a maximum potential value of $149 million, contingent on successful performance. Proposals are due by November 4, 2024, and interested parties can contact Elizabeth J. Osinski at eo43m@nih.gov or 240-550-5028 for further information.
    Determining Kinases Inhibition by GSK3 Inhibitors
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking a contractor to determine kinase inhibition by GSK3 inhibitors as part of a non-competitive procurement process. The objective is to generate 5,000 data points and 400 IC50 curves through biochemical assays to support research on CTNNB1 syndrome, a rare neurodevelopmental disorder, by profiling the efficacy of newly developed compounds against human lipid kinases. This project is crucial for advancing treatment strategies and optimizing compound design, with a contract anticipated to be awarded by September 17, 2024. Interested parties should direct inquiries to Michelle Cecilia at michelle.cecilia@nih.gov, and must ensure compliance with federal regulations as outlined in the attached documents.
    Brand-Name or Equal Axion Biosystems 48-well microelectrode array plates for the National Center for Advancing Translational Sciences
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) is seeking proposals for the procurement of Axion Biosystems 48-well microelectrode array plates, specifically the CytoView MEA 48 model, as part of a project aimed at evaluating the safety of antisense oligonucleotides in neurological treatments. The acquisition includes 10 boxes of these plates, which are crucial for conducting neurotoxicity screening assays by recording neuronal electrical signals, thereby facilitating both acute and chronic toxicity assessments. Interested vendors must submit their quotations by 4:00 PM EDT on September 9, 2024, to the Contracting Officer, Mark McNally, at mark.mcnally@nih.gov, with the anticipated award date set for September 12, 2024. The procurement is expected to follow simplified acquisition procedures, with no set-aside restrictions, and the total price must encompass all shipping and handling costs.
    A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) seek proposals from small businesses for innovative research projects under the Small Business Innovation Research (SBIR) program. The upcoming solicitation, PHS-2025-1, will open on August 2, 2024, with a closing date of October 18, 2024, and aims to foster healthcare technological innovation and commercialization. Research topics span cancer research, aging, and various health concerns. Offerors must demonstrate the technical and commercial viability of their proposals. This solicitation invites applications for Phase I, Fast Track, and Direct to Phase II projects, with evaluations based on scientific merit, commercial potential, and performance quality. Successful small businesses could receive funding for their research initiatives, contributing to NIH and CDC mission objectives.